Ke Q, Costa M, Kazantsis G. Carcinogenicity of metal compounds. In: Handbook on the Toxicology of Metals. Nordberg GF, Fowler BA, Nordberg M, Friberg LS (Eds). Elsevier, London, UK, 177-196 (2007
Livingstone SE, Mihkelson AE. Metal chelates of biologically important compounds. II. Nickel complexes of dialkyldithiophosphates and their adducts with nitrogen heterocycles. Inorg. Chem. 9(11), 2545-2551 (1970
Williams DR. Metals, ligands, and cancer. Chem. Rev. 72(3), 203-213 (1972
Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 222(5191), 385-386 (1969
Trondl R, Heffeter P, Kowol CR, Jakupec MA, Berger W, Keppler BK. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem. Sci. 5(8), 2925-2932 (2014
Galindo-Murillo R, Garcia-Ramos JC, Ruiz-Azuara L, Cheatham TE, Cortes-Guzman F. Intercalation processes of copper complexes in DNA. Nucleic Acids Res. 43(11), 5364-5376 (2015
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011
Huang R, Wallqvist A, Covell DG. Anticancer metal compounds in NCIs tumor-screening database: putative mode of action. Biochem. Pharmacol. 69(7), 1009-1039 (2005
Gianferrara T, Bratsos I, Alessio E. A categorization of metal anticancer compounds based on their mode of action. Dalton Trans. 2009(37), 7588-7598 (2009
Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. J. Med. Chem. 54(1), 3-25 (2011
Zaki M, Arjmand F, Tabassum S. Current and future potential of metallo drugs: revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. Inorg. Chim. Acta 444, 1-22 (2016
Tshuva EY, Peri D. Modern cytotoxic titanium(IV) complexes; insights on the enigmatic involvement of hydrolysis. Coord. Chem. Rev. 253(15-16), 2098-2115 (2009
Miller M, Braitbard O, Hochman J, Tshuva EY. Insights into molecular mechanism of action of salan titanium(IV) complex with in vitro and in vivo anticancer activity. J. Inorg. Biochem. doi: 10.1016/j.jinorgbio.2016.04.007 (2016) (Epub ahead of print
Manna CM, Braitbard O, Weiss E, Hochman J, Tshuva EY. Cytotoxic salan-Titanium(IV) complexes: high activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights. ChemMedChem 7(4), 703-708 (2015
Kioseoglou E, Petanidis S, Gabriel C, Salifoglou A. The chemistry and biology of vanadium compounds in cancer therapeutics. Coordin. Chem. Rev. 301-302, 87-105 (2015
Arandjelovic S, Tesic Z, Perego P, et al. Cellular sensitivity to beta-diketonato complexes of ruthenium(III), chromium(III) and rhodium(III). Med. Chem. 2(3), 227-237 (2006
Assem FL, Holmes P, Levy LS. The mutagenicity and carcinogenicity of inorganic manganese compounds: a synthesis of the evidence. J. Toxicol. Environ. Health B Crit. Rev. 14(8), 537-570 (2011
Liu J, Guo W, Li J, et al. Tumor-Targeting novel manganese complex induces ROS-mediated apoptotic and autophagic cancer cell death. Int. J. Mol. Med. 35(3), 607-6016 (2015
Zhou D-F, Chen Q-Y, Qi Y, et al. Anticancer activity, attenuation on the absorption of calcium in mitochondria, and catalase activity for manganese complexes of N-substituted di(picolyl)amine. Inorg. Chem. 50(15), 6929-6937 (2011
Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13(5), 342-355 (2013
Wani WA, Baig U, Shreaz S, et al. Recent advances in iron complexes as potential anticancer agents. New J. Chem. 40(2), 1063-1090 (2016
Gonzalez-Bartulos M, Aceves-Luquero C, Qualai J, et al. Pro-oxidant activity of amine-pyridine-based iron complexes efficiently kills cancer and cancer stem-like cells. PLoS ONE 10(9), e0137800 (2015
Chen J, Luo Z, Zhao Z, Xie L, Zheng W, Chen T. Cellular localization of iron(II) polypyridyl complexes determines their anticancer action mechanisms. Biomaterials 71, 168-177 (2015
Kwong W-L, Lok C-N, Tse C-W, Wong EL-M, Che C-M. Anti-cancer iron(II) complexes of pentadentate N-donor ligands: cytotoxicity, transcriptomics analyses, and mechanisms of action. Chem. Eur. J. 21(7), 3062-3072 (2015
Munteanu CR, Suntharalingam K. Advances in cobalt complexes as anticancer agents. Dalton Trans. 44(31), 13796-13808 (2015
Luis DV, Silva J, Tomaz AI, et al. Insights into the mechanisms underlying the antiproliferative potential of a Co(II) coordination compound bearing 1, 10-phenanthroline-5, 6-dione: DNA and protein interaction studies. J. Biol. Inorg. Chem. 19(6), 787-803 (2014
Zhang K, Zhao X, Liu J, et al. β-diketone-cobalt complexes inhibit DNA synthesis and induce S-phase arrest in rat C6 glioma cells. Oncol. Lett. 7(3), 881-885 (2014
Zhang H-R, Meng T, Liu Y-C, Chen Z-F, Liu Y-N, Liang H. Synthesis, characterization and biological evaluation of a cobalt(II) complex with 5-chloro-8-hydroxyquinoline as anticancer agent: synthesis and biological evaluation of a new Co quinoline complex. Appl. Organomet. Chem. doi: 10.1002/.aoc.3498 (2016) (Epub ahead of print
Yao Y, Costa M. Toxicogenomic effect of nickel and beyond. Arch. Toxicol. 88(9), 1645-1650 (2014
Gurumoorthy P, Mahendiran D, Kalilur Rahiman A. Theoretical calculations, DNA interaction, topoisomerase I and phosphatidylinositol-3-kinase studies of water soluble mixed-ligand nickel(II) complexes. Chem. Biol. Interact. 248, 21-35 (2016
Zhao C, Chen X, Zang D, et al. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene doi: 10.1038/onc.2016.114 (2016) (Epub ahead of print
Nagababu P, Barui AK, Thulasiram B, et al. Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers. J. Med. Chem. 58(13), 5226-5241 (2015
Zhang Z, Bi C, Schmitt SM, et al. 1, 10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity. J. Biol. Inorg. Chem. 17(8), 1257-1267 (2012
Deng J, Gou Y, Chen W, Fu X, Deng H. The Cu/ligand stoichiometry effect on the coordination behavior of aroyl hydrazone with copper(II): structure, anticancer activity and anticancer mechanism. Bioorg. Med. Chem. 24(10), 2190-2198 (2016
Denoyer D, Masaldan S, La Fontaine S, Cater MA. Targeting copper in cancer therapy: Copper That Cancer. Metallomics 7(11), 1459-1476 (2015
Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast cancer stem cell potent copper(II)-non-steroidal anti-inflammatory drug complexes. Angew. Chem. Int. Edit. Engl. Engl. 55(8), 2845-2850 (2016
Liu S, Cao W, Yu L, et al. Zinc(II) complexes containing bisbenzimidazole derivatives as a new class of apoptosis inducers that trigger DNA damage-mediated p53 phosphorylation in cancer cells. Dalton Trans. 42(16), 5932-5940 (2013
Sanyal R, Dash SK, Das S, Chattopadhyay S, Roy S, Das D. Catecholase activity, DNA cleavage and cytotoxicity of six Zn(II) complexes synthesized from designed Mannich ligands: higher reactivity of mononuclear over dinuclear. J. Biol. Inorg. Chem. 19(7), 1099-1111 (2014
Zhang H-R, Liu Y-C, Meng T, et al. Cytotoxicity, DNA binding and cell apoptosis induction of a zinc(II) complex of HBrQ. Med. Chem. Commun. 6(12), 2224-2231 (2015
Bandarra D, Lopes M, Lopes T, et al. Mo(II) complexes: a new family of cytotoxic agents? J. Inorg. Biochem. 104(11), 1171-1177 (2010
Pfeiffer H, Dragoun M, Prokop A, Schatzschneider U. Biological activity of molybdenum(II) allyl dicarbonyl complexes with N-N coligands of variable aromatic surface area on adherent and non-Adherent human cancer cells. Z. Anorg. Allg. Chem. 639(8-9), 1568-1576 (2013
Fu Y, Sanchez-Cano C, Soni R, et al. The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts. Dalton Trans. 45(20), 8367-8378 (2016
Vock CA, Ang WH, Scolaro C, et al. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J. Med. Chem. 50(9), 2166-2175 (2007
Guo L, Lv G, Qiu L, et al. Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells. Eur. J. Pharmacol. 786, 60-71 (2016
Corte-Real L, Mendes F, Coimbra J, et al. Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes. J. Biol. Inorg. Chem. 19(6), 853-867 (2014
Chen J, Li G, Peng F, et al. Investigation of inducing apoptosis in human lung cancer A549 cells and related mechanism of a ruthenium(II) polypyridyl complex. Inorg. Chem. Commun. 69, 35-39 (2016
Ma D-L, Chan DS-H, Leung C-H. Group 9 organometallic compounds for therapeutic and bioanalytical applications. Accounts Chem. Res. 47(12), 3614-3631 (2014
Ma D-L, Wang M, Mao Z, Yang C, Ng C-T, Leung C-H. Rhodium complexes as therapeutic agents. Dalton Trans. 45(7), 2762-2771 (2016
McConnell JR, Rananaware DP, Ramsey DM, Buys KN, Cole ML, McAlpine SR. A potential rhodium cancer therapy: studies of a cytotoxic organorhodium(I) complex that binds DNA. Bioorg. Med. Chem. Lett. 23(9), 2527-2531 (2013
Oehninger L, Spreckelmeyer S, Holenya P, et al. Rhodium(I) N-heterocyclic carbene bioorganometallics as in vitro antiproliferative agents with distinct effects on cellular signaling. J. Med. Chem. 58(24), 9591-9600 (2015
Zhang H-R, Liu Y-C, Chen Z-F, et al. Studies on the structures, cytotoxicity and apoptosis mechanism of 8-hydroxylquinoline rhodium(III) complexes in T-24 cells. New J. Chem. 40(7), 6005-6014 (2016
Fanelli M, Formica M, Fusi V, Giorgi L, Micheloni M, Paoli P. New trends in platinum and palladium complexes as antineoplastic agents. Coordin. Chem. Rev. 310, 41-79 (2016
Kapdi AR, Fairlamb IJS. Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes. Chem. Soc. Rev. 43(13), 4751-4777 (2014
Adiguzel Z, Baykal AT, Kacar O, Yilmaz VT, Ulukaya E, Acilan C. Biochemical and proteomic analysis of a potential anticancer agent: palladium(II) saccharinate complex of terpyridine acting through double strand break formation. J. Proteome Res. 13(11), 5240-5249 (2014
Ramachandran E, Senthil Raja D, Rath NP, Natarajan K. Role of substitution at terminal nitrogen of 2-oxo-1, 2-dihydroquinoline-3-carbaldehyde thiosemicarbazones on the coordination behavior and structure and biological properties of their palladium(II) complexes. Inorg. Chem. 52(3), 1504-1514 (2013
Wang Y, Hu J, Cai Y, et al. An oxygen-chelate complex, palladium bis-Acetylacetonate, induces apoptosis in H460 cells via endoplasmic reticulum stress pathway rather than interacting with DNA. J. Med. Chem. 56(23), 9601-9611 (2013
Haque RA, Hasanudin N, Iqbal MA, et al. Synthesis, crystal structures, in vitro anticancer, and in vivo acute oral toxicity studies of bis-imidazolium/benzimidazolium salts and respective dinuclear Ag(I)-N-heterocyclic carbene complexes. J. Coord. Chem. 66(18), 3211-3228 (2013
Eloy L, Jarrousse A-S, Teyssot M-L, et al. Anticancer activity of silver-N-heterocyclic carbene complexes: caspaseindependent induction of apoptosis via mitochondrial apoptosis-inducing factor (AIF). ChemMedChem 7(5), 805-814 (2012
Banti CN, Hadjikakou SK. Anti-proliferative and anti-Tumor activity of silver(I) compounds. Metallomics 5(6), 569-596 (2013
Jin X, Tan X, Zhang X, Han M, Zhao Y. In vitro and in vivo anticancer effects of singly protonated dehydronorcantharidin silver coordination polymer in CT-26 murine colon carcinoma model. Bioorg. Med. Chem. Lett. 25(20), 4477-4780 (2015
Li Y, Liu G-F, Tan C-P, Ji L-N, Mao Z-W. Antitumor properties and mechanisms of mitochondria-Targeted Ag(I) and Au(I) complexes containing N-heterocyclic carbenes derived from cyclophanes. Metallomics 6(8), 1460-1468 (2014
Li Y-L, Qin Q-P, An Y-F, et al. Study on potential antitumor mechanism of quinoline-based silver(I) complexes: synthesis, structural characterization, cytotoxicity, cell cycle and caspase-initiated apoptosis. Inorg. Chem. Commun. 40, 73-77 (2014
Ma C, Liang S-K, Zhao F-C, et al. Cadmium(II) complex with 2-methyl-1H-4, 5-imidazoledicarboxylic acid ligand: synthesis, characterization, and biological activity. J. Coord. Chem. 67(21), 3551-3564 (2014
Illan-Cabeza NA, Vilaplana RA, Alvarez Y, et al. Synthesis, structure and biological activity of a new and efficient Cd(II)-uracil derivative complex system for cleavage of DNA. J. Biol. Inorg. Chem. 10(8), 924-934 (2005
Lu X-M, Jiang L, Mao X-A, Ye C-H, Lu J-F, Cui J-R. Interactions with ATP, DNA cleavage and anti-Tumor activities of complexes with anions [Mo(V)O2(O2C6H4)2]3-, [Mo(V)0.5W(VI)0.5O2(O2C6H4)2]2.5- And [W(VI) O2(O2C6H4)2]2-. Chinese J. Chem. 23(6), 781-785 (2005
Leonidova A, Gasser G. Underestimated potential of organometallic rhenium complexes as anticancer agents. ACS Chem. Biol. 9(10), 2180-2193 (2014
Balakrishnan G, Rajendran T, Senthil Murugan K, et al. Interaction of rhenium(I) complex carrying long alkyl chain with Calf Thymus DNA: cytotoxic and cell imaging studies. Inorg. Chim. Acta 434, 51-59 (2015
Shtemenko NI, Chifotides HT, Domasevitch KV, et al. Synthesis, x-ray structure, interactions with DNA, remarkable in vivo tumor growth suppression and nephroprotective activity of cis-Tetrachloro-dipivalato dirhenium(III). J. Inorg. Biochem. 129, 127-134 (2013
Suntharalingam K, Awuah SG, Bruno PM, et al. Necroptosisinducing rhenium(V) oxo complexes. J. Am. Chem. Soc. 137(8), 2967-2974 (2015
Ye R-R, Tan C-P, Chen M-H, Hao L, Ji L-N, Mao Z-W. Mono- And dinuclear phosphorescent rhenium(I) complexes: impact of subcellular localization on anticancer mechanisms. Chem. Eur. J. 22(23), 7800-7809 (2016
Hearn JM, Romero-Canelon I, Munro AF, et al. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proc. Natl Acad. Sci. USA 112(29), E3800-E3805 (2015
van Rijt SH, Mukherjee A, Pizarro AM, Sadler PJ. Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells. J. Med. Chem. 53(2), 840-849 (2010
Suntharalingam K, Lin W, Johnstone TC, et al. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J. Am. Chem. Soc. 136(41), 14413-14416 (2014
van Rijt SH, Romero-Canelon I, Fu Y, Shnyder SD, Sadler PJ. Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small-cell lung cancer cells. Metallomics 6(5), 1014-1022 (2014
Hanif M, Babak MV, Hartinger CG. Development of anticancer agents: wizardry with osmium. Drug Discov. Today 19(10), 1640-1648 (2014
Meier SM, Hanif M, Adhireksan Z, et al. Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. Chem. Sci. 4(4), 1837-1846 (2013
Liu Z, Sadler PJ. Organoiridium complexes: anticancer agents and catalysts. Accounts Chem. Res. 47(4), 1174-1185 (2014
Novohradsky V, Zerzankova L, Stepankova J, et al. A dualtargeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex. Metallomics 6(8), 14911501 (2014
Yang Q, Chang J, Song J, Qian M-T, Yu J-M, Sun X. Synthesis and in vitro antitumor activity of novel iridium(III) complexes with enantiopure C2-symmetrical vicinal diamine ligands. Bioorg. Med. Chem. Lett. 23(16), 4602-4607 (2013
Liu Z, Romero-Canelon I, Qamar B, et al. The potent oxidant anticancer activity of organoiridium catalysts. Angew. Chem. Int. Edit. Engl. Engl. 53(15), 3941-3946 (2014
Gothe Y, Marzo T, Messori L, Metzler-Nolte N. Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(I)-NHC complex. Chem. Commun. 51(15), 3151-3153 (2015
Liu L-J, Lu L, Zhong H-J, et al. An iridium(III) complex inhibits JMJD2 activities and acts as a potential epigenetic modulator. J. Med. Chem. 58 (16), 6697-6703 (2015
Hearn JM, Romero-Canelon I, Qamar B, Liu Z, Hands-Portman I, Sadler PJ. Organometallic iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis. ACS Chem. Biol. 8(6), 1335-1343 (2013
Cao R, Jia J, Ma X, Zhou M, Fei H. Membrane localized iridium(III) complex induces endoplasmic reticulum stress and mitochondria-mediated apoptosis in human cancer cells. J. Med. Chem. 56(9), 3636-3644 (2013
Gibson D. Platinum(IV) anticancer prodrugs - hypotheses and facts. Dalton Trans. 45(33), 12983-12991 (2016
Komeda S. Unique platinum-DNA interactions may lead to more effective platinum-based antitumor drugs. Metallomics 3(7), 650-655 (2011
Mezencev R. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex. Curr. Cancer Drug Tar. 14(9), 794-816 (2015
Pinato O, Musetti C, Sissi C. Pt-based drugs: the spotlight will be on proteins. Metallomics 6(3), 380-395 (2014
Zou T, Lum CT, Lok C-N, Zhang J-J, Che C-M. Chemical biology of anticancer gold(III) and gold(I) complexes. Chem. Soc. Rev. 44(24), 8786-8801 (2015
Bertrand B, Stefan L, Pirrotta M, et al. Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties. Inorg. Chem. 53(4), 2296-2303 (2014
Gutierrez A, Gracia-Fleta L, Marzo I, Cativiela C, Laguna A, Gimeno MC. Gold(I) thiolates containing amino acid moieties. Cytotoxicity and structure-Activity relationship studies. Dalton Trans. 43(45), 17054-17066 (2014
Bertrand B, Spreckelmeyer S, Bodio E, et al. Exploring the potential of gold(III) cyclometallated compounds as cytotoxic agents: variations on the C-N theme. Dalton Trans. 44(26), 11911-11918 (2015
Bertrand B, de Almeida A, van der Burgt EPM, et al. New gold(I) organometallic compounds with biological activity in cancer cells: gold(I) arganometallic compounds with biological activity. Eur. J. Inorg. Chem. 2014(27), 4532-4536 (2014
Sun H, Brocato J, Costa M. Oral chromium exposure and toxicity. Curr. Envir. Health Rpt 2(3), 295-303 (2015
Luevano J, Damodaran C. A review of molecular events of cadmium-induced carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 33(3), 183-194 (2014
Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat. Res. 355(1-2), 59-70 (1996
Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid. Redox Sign. 15(4), 1085-1127 (2011
Romero-Canelon I, Sadler PJ. Next-generation metal anticancer complexes: multitargeting via redox modulation. Inorg. Chem. 52(21), 12276-12291 (2013
Geldmacher Y, Oleszak M, Sheldrick WS. Rhodium(III) and iridium(III) complexes as anticancer agents. Inorg. Chim. Acta 393, 84-102 (2012
Berners-Price SJ, Appleton TG. The chemistry of cisplatin in aqueous solution. In: Platinum-Based Drugs in Cancer Therapy. Kelland LR, Farrell NP (Eds). Humana Press, NY, USA, 3-35 (2000
Spoerlein-Guettler C, Mahal K, Schobert R, Biersack B. Ferrocene and (arene)ruthenium(II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action. J. Inorg. Biochem. 138, 64-72 (2014
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116(5), 3436-3486 (2016
Leung C-H, He H-Z, Liu L-J, Wang M, Chan DS-H, Ma D-L. Metal complexes as inhibitors of transcription factor activity. Coord. Chem. Rev. 257(21-22), 3139-3151 (2013
Diaz-Vivancos P, de Simone A, Kiddle G, Foyer CH. Glutathione-linking cell proliferation to oxidative stress. Free Radic. Biol. Med. 89, 1154-1164 (2015
Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch. Toxicol. 82(5), 273-299 (2008
Babula P, Masarik M, Adam V, et al. Mammalian metallothioneins: properties and functions. Metallomics 4(8), 739-750 (2012
Kozlowski H, Potocki S, Remelli M, Rowinska-Zyrek M, Valensin D. Specific metal ion binding sites in unstructured regions of proteins. Coord. Chem. Rev. 257(19-20), 2625-2638 (2013
Nguyen TH, Arnesano F, Scintilla S, et al. Structural determinants of cisplatin and transplatin binding to the Met-rich motif of Ctr1: a computational spectroscopy approach. J. Chem. Theory Comput. 8(8), 2912-2920 (2012
Sovago I, Varnagy K, Lihi N, Grenacs A. Coordinating properties of peptides containing histidyl residues. Coord. Chem. Rev.(2016) (In press
Bal W, Sokołowska M, Kurowska E, Faller P. Binding of transition metal ions to albumin: sites, affinities and rates. Biochim. Biophys. Acta 1830(12), 5444-5455 (2013
Kilpin KJ, Dyson PJ. Enzyme inhibition by metal complexes: concepts, strategies and applications. Chem. Sci. 4(4), 1410-1419 (2013
Verani CN. Metal complexes as inhibitors of the 26S proteasome in tumor cells. J. Inorg. Biochem. 106(1), 59-67 (2012
Tajeddine N. How do reactive oxygen species and calcium trigger mitochondrial membrane permeabilisation? Biochim. Biophys. Acta 1860(6), 1079-1088 (2016
Giampazolias E, Tait SWG. Mitochondria and the hallmarks of cancer. FEBS J. 283(5), 803-814 (2016
Wen S, Zhu D, Huang P. Targeting cancer cell mitochondria as a therapeutic approach. Future Med. Chem. 5(1), 53-67 (2013
Zhou Z, Chen F, Xu G, Gou S. Study on the cytotoxic activity of platinum(II) complexes of (1R, 2R)-N1-cyclopentyl-1, 2-cyclohexanediamine with substituted malonate derivatives. Bioorg. Med. Chem. Lett. 26(2), 322-327 (2016
Cui H, Goddard R, Porschke K-R, Hamacher A, Kassack MU. Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. Synthesis, structures, and cytotoxicity. Inorg. Chem. 53(7), 3371-3384 (2014
Travniček Z, Popa I, Čajan M, Zbořil R, Kryštof V, Mikulik J. The first iron(III) complexes with cyclin-dependent kinase inhibitors: magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe Mossbauer), theoretical, and biological activity studies. J. Inorg. Biochem. 104(4), 405-417 (2010
Medici S, Peana M, Nurchi VM, Lachowicz JI, Crisponi G, Zoroddu MA. Noble metals in medicine: latest advances. Coord. Chem. Rev. 284, 329-350 (2015
Suryadi J, Bierbach U. DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. Chem. Eur. J. 18(41), 12926-12934 (2012
Kasparkova J, Kostrhunova H, Novakova O, et al. A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew. Chem. Int. Edit. Engl. 54(48), 14478-14482 (2015
Imstepf S, Pierroz V, Rubbiani R, et al. Organometallic rhenium complexes divert doxorubicin to the mitochondria. Angew. Chem. Int. Edit. Engl. 55(8), 2792-2795 (2016
Pati ML, Niso M, Ferorelli S, Abate C, Berardi F. Novel metal chelators thiosemicarbazones with activity at the s2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment. RSC Adv. 5(125), 103131-103146 (2015
Filak LK, Goschl S, Heffeter P, et al. Metal-Arene complexes with Indolo[3, 2- c]-quinolines: effects of ruthenium vs osmium and modifications of the lactam unit on intermolecular interactions, anticancer activity, cell cycle, and cellular accumulation. Organometallics 32(3), 903-914 (2013
Piconferrer I, Huesourena F, Illancabeza N, et al. Chlorofac-Tricarbonylrhenium(I) complexes of asymmetric azines derived from 6-Acetyl-1, 3, 7-Trimethylpteridine-2, 4(1H, 3H)-dione with hydrazine and aromatic aldehydes: preparation, structural characterization and biological activity against several human tumor cell lines. J. Inorg. Biochem. 103(1), 94-100 (2009
Kouodom MN, Boscutti G, Celegato M, et al. Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy. J. Inorg. Biochem. 117, 248-260 (2012
Cucciolito ME, Litto RD, Fanizzi FP, Migoni D, Roviello G, Ruffo F. Hydrophilic ligands derived from glucose: synthesis, characterization and in vitro cytotoxic activity on cancer cells of Pt(II) complexes. Inorg. Chim. Acta 363(4), 741-747 (2010
Choi J-S, Maity A, Gray T, Berdis AJ. A metal-containing nucleoside that possesses both therapeutic and diagnostic activity against cancer. J. Biol. Chem. 290(15), 9714-9726 (2015
Huang R, Wang Q, Zhang X, Zhu J, Sun B. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed. Pharmacother. 72, 17-23 (2015
Kaps L, Biersack B, Muller-Bunz H, et al. Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. J. Inorg. Biochem. 106(1), 52-58 (2012
Biersack B, Schobert R. Metallodrug conjugates with steroids and selective estrogen receptor modulators (SERM). Curr. Med. Chem. 16(18), 2324-2337 (2009
Patra M, Awuah SG, Lippard SJ. Chemical approach to positional isomers of glucose-platinum conjugates reveals specific cancer targeting through glucose-Transportermediated uptake in vitro and in vivo. J. Am. Chem. Soc. 38(38), 12541-12551 (2016
Battistin F, Scaletti F, Balducci G, et al. Water-soluble Ru(II)- And Ru(III)-halide-PTA complexes (PTA =1, 3, 5-Triaza-7-phosphaadamantane): chemical and biological properties. J. Inorg. Biochem. 160, 180-188 (2016
Geldmacher Y, Splith K, Kitanovic I, et al. Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts. J. Biol. Inorg. Chem. 17(4), 631-646 (2012
Babak MV, Meier SM, Legin AA, et al. Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. Chem. Eur. J. 19(13), 4308-4318 (2013
Brown SD, Trotter KD, Sutcliffe OB, et al. Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity. Dalton Trans. 41(37), 11330-11339 (2012
Shi P, Jiang Q, Zhao Y, et al. DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects. J. Biol. Inorg. Chem. 11(6), 745-752 (2006
Barta Hollo B, Magyari J, Armaković S, et al. Coordination compounds of a hydrazone derivative with Co(III), Ni(II), Cu(II) and Zn(II): synthesis, characterization, reactivity assessment and biological evaluation. New J. Chem. 40(7), 5885-5895 (2016
Banerjee S, Dixit A, Karande AA, Chakravarty AR. Endoplasmic reticulum targeting tumour selective photocytotoxic oxovanadium(IV) complexes having vitamin-B6 and acridinyl moieties. Dalton Trans. 45(2), 783-796 (2016
Li H, Jensen TJ, Fronczek FR, Vicente MGH. Syntheses and properties of a series of cationic water-soluble phthalocyanines. J. Med. Chem. 51(3), 502-511 (2008
Pena B, Barhoumi R, Burghardt RC, Turro C, Dunbar KR. Confocal fluorescence microscopy studies of a fluorophorelabeled dirhodium compound: visualizing metal-metal bonded molecules in lung cancer (A549) cells. J. Am. Chem. Soc. 136(22), 7861-7864 (2014
Buchel GE, Gavriluta A, Novak M, et al. Striking difference in antiproliferative activity of ruthenium- And osmium-nitrosyl complexes with azole heterocycles. Inorg. Chem. 52(11), 6273-6285 (2013
Pelosi G. Thiosemicarbazone metal complexes: from structure to activity. TOCRYJ 3(2), 16-28 (2010
Gandioso A, Shaili E, Massaguer A, et al. An integrintargeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies. Chem. Commun. 51(44), 9169-9172 (2015
Kramer SD, Aschmann HE, Hatibovic M, et al. When barriers ignore the rule-of-five. Adv. Drug Deliver. Rev. 101, 62-74 (2016
Bacher F, Domotor O, Kaltenbrunner M, et al. Effects of terminal dimethylation and metal coordination of proline-2-formylpyridine thiosemicarbazone hybrids on lipophilicity, antiproliferative activity, and hR2 RNR inhibition. Inorg. Chem. 53(23), 12595-12609 (2014
Foteeva LS, Trofimov DA, Kuznetsova OV, et al. A quantitative structure-Activity approach for lipophilicity estimation of antitumor complexes of different metals using microemulsion electrokinetic chromatography. J. Pharmaceut. Biomed. 55(3), 409-413 (2011
He L, Li Y, Tan C-P, et al. Cyclometalated iridium(III) complexes as lysosome-Targeted photodynamic anticancer and real-Time tracking agents. Chem. Sci. 6(10), 5409-5418 (2015
Simpson PV, Schmidt C, Ott I, Bruhn H, Schatzschneider U. Synthesis, cellular uptake and biological activity against pathogenic microorganisms and cancer cells of rhodium and iridium N-heterocyclic carbene complexes bearing charged substituents: rhodium and iridium N-heterocyclic carbene complexes. Eur. J. Inorg. Chem. 2013(32), 5547-5554 (2013
deBoer-Maggard TR, Mascharak PK. Photoactivatable metal complexes and their use in biology and medicine. In: Ligand Design in Medicinal Inorganic Chemistry. Storr T (Ed.). Wiley, Chichester, UK, 355-373 (2014
Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J. Porphyr. Phthalocya. 5(2), 105-129 (2001
Gill MR, Thomas JA. Ruthenium(II) polypyridyl complexes and DNA-from structural probes to cellular imaging and therapeutics. Chem. Soc. Rev. 41(8), 3179-3192 (2012
Chen T, Liu Y, Zheng W-J, Liu J, Wong Y-S. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Inorg. Chem. 49(14), 6366-6368 (2010
Stamogiannos A, Papakyriakou A, Mauvais F-X, van Endert P, Stratikos E. Screening identifies thimerosal as a selective inhibitor of endoplasmic reticulum aminopeptidase 1. ACS Med. Chem. Lett. 7(7), 681-685 (2016
